Drug Repurposing News and Research

RSS

High-throughput screening assay could identify new prostate cancer drugs

A novel high-throughput screening assay is designed to identify inhibitors of the androgen receptor, which plays a critical role in the progression of prostate cancer.

6 Apr 2022

Study investigates targeted phenotyping of host proteins aiding drug repurposing in COVID-19

Researchers conducted selective phenotyping of coronavirus disease 2019 -relevant host proteins to facilitate target identification for drug repurposing.

4 Apr 2022

CDK6: a potential drug target for severe COVID-19

Researchers identify a methodology and workflow to repurpose drugs against the cyclin-dependent kinase 6 target gene of SARS-CoV-2.

27 Mar 2022

Study finds methylene blue is a low-micromolar inhibitor of the the SARS-CoV-2 spike protein and ACE2 interaction

A new study has focussed on screening and identification of possible SMIs of this PPI for COVID-19.

25 Mar 2022

Study unveils several natural marine products as potential agents against SARS-CoV-2

A recent study, published in the Journal of Natural Products of the American Chemical Society and American Society of Pharmacognosy, highlighted three natural marine products as potent inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – without any apparent toxic effects for human lung cells.

21 Mar 2022

Study reports thiopurines inhibit the replication of the betacoronaviruses HCoV-OC43 and SARS-CoV-2

Researchers demonstrated that the thiopurines block coronaviruses spike protein assembly and integration into progeny virions.

17 Mar 2022

In silico screening and testing of FDA approved drugs inhibiting SARS-CoV-2 spike protein cleavage

Researchers screened 5,000 Food and Drug Association-approved drugs to identify repurposed drugs targeting SARS-CoV-2 spike protein cleavage at both S1/S2 boundary and S2’.

11 Mar 2022

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.

7 Mar 2022

What does the Future of Artificial Intelligence Look Like within the Life Sciences?

In this interview, we speak to Toby Blackburn, the head of Business Development and Strategy at Emerald Cloud Lab, about the future of AI within the life science industry.

From Society for Laboratory Automation and Screening (SLAS) 14 Feb 2022

Screening assays identify TMPRSS2 inhibitors from drug repurposing candidates useful as COVID-19 therapeutic

Researchers used an assay toolset for discovering new transmembrane protease serine 2 inhibiting drug repurposing candidates, that can be useful as therapeutics for COVID-19 treatment.

10 Feb 2022

Study finds limited evidence for IL-1 blockers in treating COVID-19

Researchers assess the effectiveness and safety outcomes of interleukin-1 blocking agents in the treatment of COVID-19.

31 Jan 2022

Treating COVID with antibiotics could be a much simpler way of making people better

A recent study conducted in an Egyptian hospital showed that treating moderate-to-severe COVID patients with either one of two antibiotics (ceftazidime or cefepime, in combination with a steroid) resulted in similar recovery times compared to patients given standard treatment.

29 Jan 2022

Boceprevir-based molecules show high antiviral potency against SARS-CoV-2

In a study posted to the bioRxiv* pre-print server, a team of researchers conducted a structure-activity relationship study of boceprevir-based molecules to find antiviral drug candidates targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease MPro.

22 Dec 2021

Study suggests nitazoxanide fails to reduce the severity of SARS-CoV-2

A new study shows that the optimization of nitazoxanide formulations may allow the review of the potential use of the drug for the treatment of SARS-CoV-2 infection.

22 Dec 2021

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

A new paper deals with the identification of an antiviral compound that could help in developing additional drugs to help fight COVID-19.

30 Nov 2021

Study finds no evidence to support favipiravir use in mild or asymptomatic COVID-19 patients

Researchers conducted a Phase II randomized placebo-controlled, double-blinded trial between July 8, 2020, and March 23. 2021.

28 Nov 2021

Researchers identify never-before-defined subtypes of a blood cancer

Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.

17 Nov 2021

Drug Repurposing News and Research

High-throughput screening assay could identify new prostate cancer drugs

Study investigates targeted phenotyping of host proteins aiding drug repurposing in COVID-19

CDK6: a potential drug target for severe COVID-19

Study finds methylene blue is a low-micromolar inhibitor of the the SARS-CoV-2 spike protein and ACE2 interaction

Study unveils several natural marine products as potential agents against SARS-CoV-2

Study reports thiopurines inhibit the replication of the betacoronaviruses HCoV-OC43 and SARS-CoV-2

In silico screening and testing of FDA approved drugs inhibiting SARS-CoV-2 spike protein cleavage

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

What does the Future of Artificial Intelligence Look Like within the Life Sciences?

Screening assays identify TMPRSS2 inhibitors from drug repurposing candidates useful as COVID-19 therapeutic

Study finds limited evidence for IL-1 blockers in treating COVID-19

Treating COVID with antibiotics could be a much simpler way of making people better

Boceprevir-based molecules show high antiviral potency against SARS-CoV-2

Study suggests nitazoxanide fails to reduce the severity of SARS-CoV-2

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

Study finds no evidence to support favipiravir use in mild or asymptomatic COVID-19 patients

Researchers identify never-before-defined subtypes of a blood cancer

Cancer drugs could be repurposed as potential therapies for Alzheimer's disease

Invalidation of potential SARS-CoV-2 protease inhibitors

Can targeting autophagy become a new approach to COVID-19 treatment?

Drug Discovery - Second Edition eBook

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest News